With New Breast Cancer Treatments Come Lasting Toxicity
About a third of breast cancer survivors are still living with fatigue and reduced exercise capacity after treatment ends.
Erdafitinib Reduces Risk of Death by 36% in FGFR-Altered Urothelial Cancer
Nirogacestat Significantly Reduces Pain Severity in Patients With Desmoid Tumors
Dostarlimab Maintains HRQOL in 3-Year Follow-Up Of Patients With Early Endometrial Cancer
Patients With uHCC Who Experience irAEs With Tremelimumab/Durvalumab Achieve Numerical Improvements in OS
2 Clarke Drive Cranbury, NJ 08512